Esperion Therapeutics, Inc. (ESPR)
| Market Cap | 474.85M |
| Revenue (ttm) | 295.45M |
| Net Income (ttm) | -86.77M |
| Shares Out | 197.04M |
| EPS (ttm) | -0.52 |
| PE Ratio | n/a |
| Forward PE | 13.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,263,682 |
| Open | 2.380 |
| Previous Close | 2.410 |
| Day's Range | 2.305 - 2.450 |
| 52-Week Range | 1.160 - 3.400 |
| Beta | 0.95 |
| Analysts | Buy |
| Price Target | 8.17 (+239.0%) |
| Earnings Date | Nov 7, 2024 |
About ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products als... [Read more]
Financial Performance
In 2023, Esperion Therapeutics's revenue was $116.33 million, an increase of 54.14% compared to the previous year's $75.48 million. Losses were -$209.25 million, -10.45% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is $8.17, which is an increase of 239.00% from the latest price.
News
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo –
Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy
I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization ...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs) under ...
Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth –
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesd...
Esperion to Report Third Quarter 2024 Financial Results on November 7
ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024.
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs) under ...
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insur...
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment Confer...
Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs
Meeting expectations with revenue growth, expense guidance, and sales execution. Potential overhang from financial engineering with complex deals, warrants, and generic litigants. Maintaining a buy ra...
Esperion Therapeutics: Strategically Positioned To Grow
Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving sign...
Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
– Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of $28.3 Million, Representing 39% Growth –
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) –
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
– OMERS Life Sciences to Purchase Esperion's European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment –
Esperion to Participate in Upcoming June Investor Conferences
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, wh...
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Ja...
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism...
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for b...
Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koenig - ...
Esperion Reports First Quarter 2024 Financial Results
– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43% Y/Y ...
Esperion to Participate in Upcoming May Investor Conferences
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, ...
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo –
Esperion Therapeutics (ESPR) CEO on Cholesterol Lowering Medications
Esperion Therapeutics (ESPR) specializes in cholesterol lowering medications. President and CEO Sheldon Koenig joins Nicole Petallides to give an overview of the company.